Teligent Calls In The Cavalry As Warning Letter Threatens To Overwhelm

Debt-To-Equity Swap Of $77m Announced; Additional Liquidity Provided

Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.

Cavalry Horses Army Battle
Teligent's outstanding funded debt has been reduced from $223 million at 30 June last year to approx. $105m • Source: Shutterstock

Struggling Teligent has announced a recapitalization plan with senior lenders and noteholders to strengthen its balance sheet while raising additional capital, with the primary goal of having the means to remedy a US Food and Drug Administration Warning Letter against its manufacturing facility in Buena, New Jersey.

Noteholders and lenders have eased some of the pressure on the US-based player by converting around $77m of total debt...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business